Document Detail


Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
MedLine Citation:
PMID:  21432858     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: There is a growing body of evidence that blood pressure (BP) level is one of the major determinants of cardiovascular morbidity and mortality in individuals, including elderly people. However, to achieve a target BP level in the elderly is more difficult compared with patients aged <65 years. Current guidelines recommend combination drug therapy with different modes of action for the treatment of elderly patients with moderate hypertension (HT). However, the optimal combination regimen is not well established in elderly HT.
HYPOTHESIS: We hypothesized that combination therapy of telmisartan plus amlodipine would exert favorable cardiometabolic actions in elderly HT.
METHODS: Seventeen elderly patients with essential HT who failed to achieve a target home BP level with treatment of 5 mg amlodipine plus 80 mg valsartan or 8 mg candesartan for at least 2 months were enrolled. Then the patients were assigned to replace their valsartan or candesartan with 40 mg telmisartan. The subjects were instructed to measure their own BP at home every day during the study periods.
RESULTS: Replacement of valsartan or candesartan by telmisartan in amlodipine-treated elderly hypertensive patients showed a significant reduction in morning home systolic BP and evening home systolic and diastolic BP at 12 weeks. Switching to telmisartan significantly increased serum adiponectin level.
CONCLUSIONS: Our present study suggests that combination therapy with telmisartan plus amlodipine may exert more beneficial cardiometabolic effects in elderly patients with HT compared with valsartan or candesartan plus amlodipine treatment.
Authors:
Hisatoshi Bekki; Kiichiro Yamamoto; Masayoshi Sone; Tomoki Homma; Masashi Nakata; Masatoshi Nohara; Kei Fukami; Seiya Okuda; Sho-ichi Yamagishi
Related Documents :
7633738 - Surfactant protein a predicts survival in idiopathic pulmonary fibrosis.
21523338 - Nilotinib as frontline therapy for patients with newly diagnosed ph+ chronic myeloid le...
21249058 - Part i: the difficult patient: medical and legal approaches.
21171848 - Clinical profile and outcome of patients hospitalized with dimethyl and diethyl organop...
23645008 - Characteristics and outcomes of patients administered blood in the prehospital environm...
2890428 - 2'-deoxycoformycin therapy in adult t-cell leukemia/lymphoma.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2011-02-01
Journal Detail:
Title:  Clinical cardiology     Volume:  34     ISSN:  1932-8737     ISO Abbreviation:  Clin Cardiol     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-04-04     Completed Date:  2011-07-25     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  7903272     Medline TA:  Clin Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  261-5     Citation Subset:  IM    
Copyright Information:
© 2011 Wiley Periodicals, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adiponectin / blood
Age Factors
Aged
Aged, 80 and over
Amlodipine / therapeutic use*
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Antihypertensive Agents / therapeutic use*
Benzimidazoles / therapeutic use*
Benzoates / therapeutic use*
Blood Pressure / drug effects*
Calcium Channel Blockers / therapeutic use*
Drug Substitution
Drug Therapy, Combination
Female
Humans
Hypertension / blood,  drug therapy*,  physiopathology
Japan
Male
Prospective Studies
Tetrazoles / therapeutic use
Time Factors
Treatment Outcome
Up-Regulation
Valine / analogs & derivatives,  therapeutic use
Chemical
Reg. No./Substance:
0/ADIPOQ protein, human; 0/Adiponectin; 0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Benzoates; 0/Calcium Channel Blockers; 0/Tetrazoles; 137862-53-4/valsartan; 1J444QC288/Amlodipine; HG18B9YRS7/Valine; S8Q36MD2XX/candesartan; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of Prognostic Outcome Between Left Circumflex Artery-Related and Right Coronary Artery-Re...
Next Document:  Serial Angioscopic Evaluation of Neointimal Coverage and Incidence of Thrombus Formation After Pacli...